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BACKGROUND: There is evidence that tumours produce substances such as cytokines and microvesicular bodies bearing bioactive
molecules, which support the carcinogenic process. Furthermore, chemotherapy has also been shown to modify these exudates and
in doing so, neutralise their tumourigenic influence.
METHODS: In the current study, we have investigated the effect of chemotherapy agents on modifying the cytokine profile and
microvesicular cargo of supernatants derived from cancer cell lines. In addition, we have explored the effect of these tumour-derived
supernatants on angiogenesis, and how chemotherapy can alter the supernatants rendering them less pro-angiogenic.
RESULTS: Herein, we show that supernatants contain a rich cocktail of cytokines, a number of which are potent modulators of
angiogenesis. They also contain microvesicular bodies containing RNA transcripts that code for proteins involved in transcription,
immune modulation and angiogenesis. These supernatants altered intracellular signalling molecules in endothelial cells and significantly
enhanced their tubulogenic character; however, this was severely compromised when supernatants from tumours treated with
chemotherapy was used instead.
CONCLUSION: This study suggests tumour exudates and bioactive material from tumours can influence cellular functions, and that
treatment with some chemotherapy can serve to negate these pro-tumourigenic processes.
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We have previously shown that some chemotherapies are able
to affect immune modulation (Liu et al, 2010). This is manifest
in two ways, first chemotherapy can upregulate class I human
leucocyte antigen expression on tumours directly, which leads
to an improved adaptive response. Second, an indirect effect of
chemotherapy is possible as supernatant derived from tumours
treated with standard drugs such as oxaliplatin (OXP) or
gemcitabine can enhance the function of dendritic cells (DCs).
Specifically, DCs exposed to these supernatants have an enhanced
maturation phenotype, which in turn increases the activation and
proliferation of T-lymphocytes, and ultimately the cytolytic ability
of these effector cells. The effects on DCs were apparent at the level
of gene expression, with the supernatants being capable of
modifying the expressions of DC markers such as CCR7, CD80
and CD86 (Liu et al, 2012).
It appears that chemotherapy can hijack tumours resulting in
their producing substances that are anti-tumour in character.
Moreover, as tumours seem to intrinsically produce these
substances, chemotherapy may actually serve to negate/neutralise
the action of tumour-derived supernatants. Indeed, the presence of
a bridge of communication between tumours and the host
microenvironment suggests its role in the tumourigenic process
(Joyce and Pollard, 2009). Communication can be direct through
tumour-to-stroma contact, or via an indirect mechanism such as
supernatants drawn from tumours. These supernatants invariably
reflect the cellular and biochemical makeup of the tumour, and can
exhibit a repertoire of cytokines (Dranoff, 2004). Their compo-
nents appear to support tumourigenesis, but the particular roles
they have in the process are unclear. However, we have shown that
tumour-derived cytokines can support angiogenesis (Liu et al, 2009),
and directly maintain an immunosuppressive microenvironment
conducive to cancer development (Dalgleish and O’Byrne, 2002).
Supernatants can also include cellular fragments, apoptotic
bodies and other plasma membrane-derived vesicles. These
microvesicular structures have been detected in a number of
biological fluids including blood and ascitic fluid, and are thought
to be involved in communication between cells, including cross
talk between tumour cells and host (Thery et al, 2002). In a similar
way to cytokines, microvesicles derived from some tumours can
have a part in suppressing immune responses directed towards the
cancer, as well as modifying the tumour microenvironment to
support tumourigenesis. Although the exact mechanism by which
this extracellular communication is achieved is unknown, RNA
and microRNA material have been found within the vesicles as well
as adhered to these microparticles, thus rendering them transla-
table protagonists (Valadi et al, 2007; Pegtel et al, 2010). The
resulting effects have included increased metastatic potential and
modulation of angiogenesis (Hood et al, 2011; Taverna et al, 2011).
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As part of our ongoing research studies, we have examined more
closely the role of supernatants derived from cancer cell lines
before and after treatment with chemotherapy in modifying the
interaction between these cells and the host microenvironment.
We have worked on the hypothesis that supernatants contain
bioactive substances derived from tumours, which modify the
tumour-host relationship in a way that is favourable for
tumourigenesis. We have as part of this approach, analysed the
cytokine profiles of supernatants, in addition to employing gene
microarray analysis to identify key transcripts present in the
microvesicles that may be involved in this oncogenic process. The
effect that common chemotherapy has on the constitution of these
supernatants has also been assessed.
MATERIALS AND METHODS
Cell culture
The human cancer cell lines A549 (lung), HCT116 (colon), MCF7
(breast) and human umbilical vein endothelial cells (HUVECs)
were obtained from the Cancer Research UK Cell Production
Laboratories (Potters Bar, UK). All cells were maintained in culture
medium supplemented with 10% (v/v) foetal bovine serum (FBS),
2mM L-glutamine and 1% penicillin/streptomycin (basal culture
medium). All cell lines were incubated in a humidified atmosphere
with 5% CO2 in air at 37 1C, and cancer cell lines were discarded
when the passage number exceeded 15.
Reagents
Cyclophosphamide (CPM: Sigma Ltd., Dorset, UK) and OXP
(Sigma) were dissolved in phosphate buffered saline (PBS) to
create 10mM stock solutions that were maintained at 20 1C for
no longer than 4 weeks. All controls used in our studies involved
treatment with equal amounts of PBS.
Generating tumour-derived supernatants
Supernatants were decanted from these cultures as described
previously (Liu et al, 2012). Briefly, exhausted media (super-
natants) were obtained from cells either cultured alone, with
100mM CPM or with 1 mM OXP for 72 h. These concentrations were
the approximate IC25 s for the drugs as reported previously
(Liu et al, 2010). All supernatants were stored at 20 1C, and
freeze–thaw cycles kept to a minimum by aliquoting.
Cytokine analysis of supernatants
The profile of 46 cytokines and analytes associated with
inflammation were determined in each of the supernatants by
a proprietary multiplex immunoassay solution (Rules Based
Medicine Inc., Austin, TX, USA). In addition, the levels of VEGF
were assayed using an ELISA kit according to the manufacturer’s
instructions (R&D Systems, Oxford, UK).
Isolation of microvesicles from supernatants
Small cellular vesicles and microparticles were isolated by
sequential centrifugation at 4 1C using increasing forces. These
were loosely defined as microvesicles. Culture supernatants were
initially centrifuged at 300 g for 10min, and then transferred to a
fresh tube for a second spin at 2000 g for 10min. These steps
allowed for the separation of live and dead cells, respectively.
Supernatants were then centrifuged for a third time at 10 000 g for
30min as a way of removing cellular debris. The supernatants were
then transferred to fresh tubes, and ultra-centrifuged at 100 000 g
for 70min, before transferring the supernatants to a fresh tube.
These samples were defined as the ‘cytokine fraction’. The remaining
pellets were then re-suspended in PBS. A final spin at 100 000 g for
70min was performed before supernatants were aspirated, yielding
pellets of microvesicles that were stored at 80 1C until required.
RNA extraction
RNA was extracted from microvesicles collected from the super-
natants of A549 cells cultured alone, with CPM or with OXP. RNA
was purified by Trizol, followed by precipitation with iso-propanol.
The RNA pellet was washed in 70% (v/v) ethanol, air dried, re-
suspended in RNase-free water and stored at 80 1C. RNA
concentration and purity were measured using a NanoDrop ND
1000 spectrophotometer (NanoDrop Technologies, Wilmington, DE,
USA), and RNA integrity was determined by an Agilent 2100
Bioanalyser (Agilent Technologies UK Ltd., Stockport, UK) using
RNA 6000 Nano LabChips (Agilent). RNA integrity was expressed in
terms of an RNA integrity number as determined by the proprietary
software and only those with values of 49.0 were progressed.
Illumina microarrays
Biotinylated cRNA was generated from 100 ng total RNA using the
Illumina Total Prep RNA Amplification Kit (Applied Biosystems,
Warrington, UK) according to manufacturer’s instructions. The
concentration and purity of resultant cRNA was determined
using the NanoDrop ND 1000 spectrophotometer (NanoDrop
Technologies). Equal amounts (750 ng) of cRNA were hybridised
to the Illumina human HT12-v3 arrays (Illumina UK, Saffron
Walden, UK) for 18 h and subsequently processed according to
manufacturer’s instructions before scanning on an Illumina Bead
Array Reader (Illumina UK). The image data were processed using
default values in Genome Studio v2009.1 (Illumina, UK), before
loading onto Gene Spring v9.0 (Agilent Technologies UK Ltd.) for
data normalisation and filtering. Analyses were performed using
gene ontology databases within Pathway Studio v7.1 (Ariadne
Genomics, Rockville, MD, USA). A greater than 0.25-fold change
was used as our cutoff magnitude for gene list compositions by
using Excel software (Microsoft UK, Reading, UK).
Tubule-formation assay
The vasculogenic natures of supernatants, microvesicles and
cytokine fractions were assessed by their ability to induce the
reorganisation on HUVECs into primitive tubules. A layer (150 ml)
of growth factor reduced Matrigel matrix was allowed to set in
six-well plates for 30min, before layering on HUVECs (5 105 in
medium). This medium was either (i) complete supernatants
(500ml) derived from A549 cells cultured with chemotherapy; or
(ii) isolated microvesicles re-suspended at a protein concentra-
tion of 10 mg per 500 ml in PBS; or (iii) cytokine fraction (500 ml).
Samples were incubated in a humidified atmosphere with 5% CO2
in air at 37 1C for 16 h, before visualising tubules under light micro-
scopy. Tubule formation was quantified by using the programme
AngioQuant (http://www.cs.tut.fi/sgn/csb/angioquant/).
Immunoblotting analysis
Cells were harvested and total cellular protein was solubilised in
lysis buffer (New England Biolabs, Hitchin, UK) and resolved by
tris-glycine electrophoresis using a 4–12% bis-tris gradient-gel.
Following transfer of proteins to 0.45mm nitrocellulose mem-
branes, blocking was performed in 5% (w/v) non-fat milk in TTBS
(0.5% (v/v) Tween-20 in tris buffered saline (50mM Tris base with
150mM NaCl; pH 7.6)). Primary antibody probing was performed
with anti-AKT, anti-phospho AKT, anti-ERK and anti-phospho
ERK. All primary antibodies were obtained from New England
Biolabs and used at a dilution of 1 : 1000, unless stated otherwise.
Anti-b actin was used as a loading control (1 : 2000 – New England
Biolabs). Following three washing steps in TTBS, horseradish
Tumour-supernatants modify angiogenesis
WM Liu et al
897
British Journal of Cancer (2012) 106(5), 896 – 903& 2012 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
st
ic
s
peroxidase-conjugated anti-species IgG1 was used as the secondary
antibody (Amersham Biosciences Ltd., Little Chalfont, UK). Bands
were visualised by the ECL-plus detection system (Amersham).
RESULTS
Tumour-derived supernatants contain cytokines
The profiles of cytokines in the supernatants derived from cell
lines were assessed by a multiplex immunoassay, where 46 analytes
associated with inflammation were quantified. The effect of
treating cells with equi-active concentrations of CPM or OXP on
cytokine profiles was also established. Only those analytes that
were detectable are presented. Results indicated that the super-
natants contained variable amounts of cytokines, which were
different in the cell lines studies (Figures 1A–C). Specifically,
HCT116 cells produced supernatants that consisted of 13
cytokines, compared with 6 and 4 for A549 and MCF7,
respectively; and there were no cytokines that were common to
all three tumours. Culturing cells with CPM did not affect the levels
of these cytokines in the cells; however, there was a divergence in
the levels of the cytokines after treatment with OXP. Cytokines
were thus ordered according to the difference in amounts between
untreated and OXP-treated samples, and VEGF was seen to be
altered to the greatest extent. The amount of VEGF in the
supernatants were then re-assessed by ELISA, and results showed
that they were significantly decreased after treatment with OXP in
A549 (1.1±0.55 pgml1 vs 36±2.4 pgml1 in untreated controls)
and in HCT116 (571±29 pgml1 vs 1741±48 pgml1 in untreated
controls) (Both Po0.001 Figure 1D).
Tumour-derived supernatants can support vasculogenesis
We next tested the vasculogenic nature of supernatants by
culturing them with HUVECs and assessing the extent to which
they re-arranged into primitive tubules when grown upon
Matrigel. The supernatants were deconstructed by differential
ultra-centrifugation into microvesicular and cytokine fractions.
The protein contents of the microvesicular fractions were assessed
by a proprietary bicinchoninic acid assay kit (Fisher Scientific UK
Ltd., Loughborough, UK) (Figure 2A), and then used at a
concentration of 10 mg per 500ml in PBS. There was thus a total
of three samples assessed: (1) complete supernatant, (2) micro-
vesicular fraction and (3) cytokine fraction.
Results showed that culturing HUVECs with standard culture
medium or with basal medium spiked with 100 mM of CPM or 1 mM
1 000 000
HCT116
Analyte
VEGF
P <0.001
P =0.082
P =0.930
P =0.769
P <0.001
P =0.367
A549
Analyte
Co
nc
en
tra
tio
n 
(pg
 m
l–1
)
Co
nc
en
tra
tio
n 
(pg
 m
l–1
)
Co
nc
en
tra
tio
n 
(pg
 m
l–1
)
Co
nc
en
tra
tio
n 
(pg
 m
l–1
)
100 000
10 000
1000
100
10
AAT IL6
IL8 IL6
SCF
SCF MIPI
CCL11
CCL11
BDNF IL1R IL1TIMP1
TIMP1
VCAM1
VCAM1
Analyte
2M
2M
IL23 VEGF
VEGF
A549 HCT116 MCF7
Cell line
Cont
CPM
OXP
Cont
CPM
OXP
Cont
CPM
OXP
Cont
CPM
OXP
2M
2M
1
1 000 000
100 000
10 000
1000
100
10
1
1 000 000 MCF7
100 000
10 000
1000
100
10
1
10 000
1000
100
10
0.1
1
Figure 1 Effects of treatment on cytokine profile. A549, HCT116 and MCF7 cells were cultured with PBS (Cont), CPM or OXP for 72 h before assessing
the levels of 46 analytes by a multiplex immunoassay (A–C). The amounts of VEGF in the supernatants were also specifically assessed by ELISA (D).
Data for VEGF represent the mean and s.d.s of three separate experiments, and P-values are from paired t-tests.
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of OXP for 72 h, resulted in no tube formation (Figure 3). However,
culturing with CONT-supernatant significantly increased the
capacity of HUVECs to form tube-like structures. This was
enumerated by measuring the total lengths of tubule-complexes
by using the dedicated image analysis tool AngioQuant, which
reported an increase from 0 to 2806±225 a.u. (Figure 3).
Furthermore, all cells were confirmed viable by trypan blue
exclusion analysis. CPM-supernatants also resulted in a similar
extent of tubulogenesis (paired t-test vs controls: P¼ 0.161);
however, OXP-supernatant significantly reduced the level of tube
formation (1362±192 vs 2806±225 in CONT-supernatant;
P¼ 0.006). The trend in tubulogenesis following stimulation
with cytokine fractions was similar to that seen with complete
supernatants, in that the level of network formation was high
in CONT and CPM samples, but significantly reduced in OXP
samples (961±57 vs 2193±211; P¼ 0.003). HUVECs stimulated
with microvesicles generally resulted in fewer tubes as compared
with the number seen with complete supernatants. Specifically,
although microvesicles from untreated tumours significantly
increased tubule formation, the amount was much lower than
that induced by complete medium (842±91 vs 2806±225;
Po0.001) (Figure 3). There was no difference in the tubulogenic
nature of microvesicles from CPM-treated and untreated tumours
(P¼ 0.886). Conversely, those from OXP-treated tumours had
slightly increased tubulogenic capability, which did not reach
significance (P¼ 0.064) (Figure 3).
Tumour-derived supernatants alter the expressions of AKT
and ERK
To investigate whether the changes in vasculogenesis were linked
with modifications to key intracellular signalling pathways, whole-
cell lysates were obtained from HUVECs cultured with the
supernatants and the levels of AKT and ERK assessed by
immunoblotting. This panel was chosen as they broadly repre-
sented key proteins involved in modifying angiogenesis and
neovascularisation. The intention was to employ this approach to
identify whether or not a change in intracellular signalling was
involved in triggering the phenotypic changes, which could
ultimately provide putative targets against which therapies could
be adapted. Results highlighted increases in active AKT and ERK
proteins following culture with CONT-supernatants and CPM-
supernatants (Figure 2B). However, these increases were not seen
in HUVECs cultured with OXP-supernatant, and their levels
remained virtually unchanged compared with HUVECs in basal
medium (Figure 2B).
Sample-descriptions, microarray data quality control,
filtering and pre-processing
There were two independent sets of microvesicles harvested from
A549 tumour cells in separate experiments, and each set comprised
of three treatment conditions: (i) untreated; (ii) CPM-treated and
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Figure 2 Microvesicles are altered by treatment. A549, HCT116 and MCF7 cells were cultured with PBS (U), CPM (C) or OXP (O) for 72 h before
microvesicles were extracted. The protein content of these particles from 10ml of supernatant was assessed by BCA testing (A).The effects of supernatants
on the ERK and PI3-K in HUVECs were also examined by western blotting (B). þ ve refers to effects of endothelial cell medium. Venn analysis of the genes
called present in the microvesicles following treatments revealed a large number of genes was common to each condition (C). *Po0.05 by paired t-tests. All
supernatant samples naturally included FBS as part of the exhausted media from which they were derived, and changes in the microvesicle portion would
account for any microvesicles derived from FBS.
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(iii) OXP-treated, from which RNA was extracted. The qualities of
the RNA from each of the samples were confirmed by Illumina
software (Illumina), and all controls (hybridisations, negative,
spike-ins, etc) were within the guidelines as specified by the
manufacturer. All pre-normalised intensity signals from each
probe were collated and those genes whose expressions were below
the baseline/background value of 60 were defined as absent.
Additionally, those probes with no names or those designated
‘predicted genes’ were also excluded. This filtering process
trimmed the number of genes from 45 599 to 28 557. Differences
in the magnitudes of gene expressions between any of the
treatment groups were then analysed using Excel software.
Comparing the transcriptomes of microvesicles
An initial survey of the genes showed there to be a very small
number present in the microvesicles. For instance, there were just
92 hits from a possible 28 557 genes (0.32%) in the microvesicles
from the supernatants of untreated tumour cells. Full gene lists
are available at GeneExpress (www.ebi.ac.uk – accession number
E-TABM-1201). A large proportion of these genes possessed
similar functions, so gene ontological analysis using Pathway
Studio was performed on this list. Categories were then defined
and ranked in order of the percentage of genes found. The leading
categories were regulation of transcription (15% (12/92)), and
genes for membrane components (27% (25/92)) (Table 1). The
expressions of these 92 genes were then established in the
microvesicles harvested from tumours cultured with CPM or
OXP (Table 1). Venn analysis of all the transcripts called present in
the microvesicles from any of treatments showed a proportion of
them was common (Figure 2C). There were overlapping genes
unique to CPM or OXP with the untreated sample (28 and 14,
respectively), but few between CPM and OXP (3) (Figure 2C).
In an attempt to understand the genetic backdrop of the general
observation that the vasculogenic action of microvesicles were not
different between CPM and untreated samples but different in
OXP-treatment, a second list of genes were created that complied
with the criteria that expressions be (i) o10% different between
untreated and CPM-treated, and (ii) 41-fold change in either
direction between untreated and OXP-treated (Table 2). Further-
more, this approach was also in accordance with our previous
published data that indicated CPM generally affected cells to a
lesser degree than OXP (Liu et al, 2010, 2012). Analysis revealed
just 13 genes (0.046%) conformed to these criteria, and that a
number of them (il18, lilrb1, krit1, abca4 and map1a) were
associated with angiogenesis and neovascularisation.
DISCUSSION
This study was initiated in response to our earlier reports defining
a novel potential immune-stimulatory feature of some common
chemotherapy agents. In these studies, we showed an enhancement
to cell-mediated immune responses by supernatants derived from
tumour cells, and that these were affected by drug treatments
(Liu et al, 2010). Therefore, the aim of the current study was to
explore the biological nature of these supernatants. To this end,
we deconstructed the supernatants into cytokine and micro-
vesicular fractions, and employed molecular biological techniques
to establish the effect on cellular processes of the individual
contributions of these parts. Our results showed that the super-
natants were rich in cytokines with the capacity to alter
angiogenesis, as well as containing microvesicles loaded with
RNA material. These supernatants altered intracellular signalling,
reorganised the phenotype of HUVECs, and thus modified the
process of tubulogenesis. Importantly, our data also supported the
idea that some chemotherapy could negate these effects, and hence
minimise the impact of these neoplastic events.
Cancer cells produce a heterogeneous mixture of material that
has been loosely referred to as debris, apoptotic fragments or
microvesicular matter. Rather than being haphazard and inert in
nature, they have been shown to be organised into vesicles
filled with bioactive material (Thery et al, 2002). Their presence
in biological fluids such as blood, urine and ascites supports
their role in cell-to-cell communication, and suggests an involve-
ment in the carcinogenic process (Zhang and Grizzle, 2011).
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Figure 3 The effect of supernatants on tubulogenesis. HUVEC were cultured with the supernatants derived from A549 cells, and the potential of
HUVECs cells to form primitive tube-networks was assessed upon growth factor reduced Matrigel. Tube formation was seen when HUVECs were cultured
with CONT-supernatants; however, this was significantly reduced when OXP-supernatants were used. Standard culture medium (basal medium) for
tumours induced no tube-formation, as did basal medium spiked with CPM or OXP. Supernatants were then deconstructed into a microvesicular fraction
and a cytokine fraction (cyt. fraction), and the effects that these components had on tubulogenesis also assessed. AngioQuant software (see text) was
employed to enumerate tube formation, and the values represent the means and s.d.s of four separate samples.
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The overlapping association of these microvesicles with soluble
factors such as cytokines, which together are constantly exuded by
tumours generates a potent mixture that is capable of transmitting
developmental cues between tumour and host cells. It would be
valuable to identify the key elements in the supernatants as this
would assist in developing new therapeutic methods that would
negate or minimise their impacts. Not only that, this would also
help us understand our earlier data. For that reason, we assessed
the cytokine fraction of the supernatants by using a multiplex
immunoassay that simultaneously quantified 46 analytes related to
inflammation. Results showed that the cytokines identified in the
supernatants were varied and tumour specific. The specific roles
and impacts of these analytes were not assessed; however, it
appeared that a number of these were associated with angiogen-
esis. In particular, there were a number of analytes with strong
links to neo-vascularisation that were detected in the supernatants
of untreated HCT116 cells, and of these, we focused primarily on
VEGF, the cytokine that was altered the greatest.
In addition to our initial multi-analyte profiling approach, we
also separated the microvesicular fraction from the soluble and
debris fractions of the supernatants by differential ultra-centrifu-
gation (Thery et al, 2006), and assessed the genetic cargo of these
membrane bound particles by microarray analysis. Technically,
this population of microvesicles would have been mixed with those
shed by FBS (Heijnen et al, 1999). However, as FBS was present
in all our supernatants, any changes to their profile would be
Table 1 Top-40 genes present in tumour microvesicles
Gene expression Gene expression
CON CPM OXP Symbol Notes CON CPM OXP Symbol Notes
3193 3193 3193 LAIR1 Leukocyte immunoglobulin-like receptor 1 438 132 910 SALL3
2720 2720 2720 IMAA Pseudogene 421 417 383 CDAN1 Congenital dyserythropoietic anaemia type 1
2146 2084 2146 CLUAP1 Clusterin-associated protein 1 395 371 194 GABPB2 GA-binding protein transcription factor b subunit 2
2022 2084 2022 F2R Thrombin receptor 387 438 362 SHCBP1 Associated with intracellular signalling
1464 1464 1387 C19orf31 383 352 200 SLC44A4 Solute carrier
1310 1310 1172 FARSLB Phenylalanyl-tRNA synthetase, b subunit 367 464 328 MSH3 Component of the DNA mismatch repair system
1172 1172 1387 NAG18 366 444 217 MGC16703
985 971 965 ITIH5 Inter-a inhibitor H5 364 362 188 C21orf55
971 968 955 ROCK2 Rho kinase 2 336 309 66 PNPT1 Polynucleotide phosphorylase 1
955 971 874 LILRB3 Leukocyte immunoglobulin-like receptor 3 330 304 76 IL18 Interleukin 18
929 929 955 ORC6 L Origin recognition complex subunit 6 325 327 51 RPL7L1 Ribosomal protein
743 740 683 LOC400721 318 103 659 FGA Processes fibrin
708 740 616 KIAA0101 Associated with proliferating cell nuclear antigen 312 273 53 LOC729603 Calcium binding
680 631 631 CCR6 Chemokine receptor 6 291 357 170 CREB1 cAMP response element-binding protein
648 648 521 AKR1D1 Aldo-keto reductase family 1, member D1 282 295 50 GJC1 Gap junction protein
599 580 548 LOC389517 Pseudogene 281 359 73 PDCD7 Promoter of apoptosis
529 463 180 FAM177A1 255 311 51 LOC642947
485 504 466 PDE4C Phosphodiesterase 4C 255 277 47 FKTN Fukutin
475 570 537 RN7SL1 Cytoplasmic ribonucleoprotein complex 230 253 59 LILRB1 Leukocyte immunoglobulin-like receptor 1
453 399 337 AIRE Involved in self tolerance and autoimmunity 200 251 47 SLC16A12 Solute carrier
Abbreviations: CON¼ control; CPM¼Cyclophosphamide; OXP¼ oxaliplatin. Spot-intensity signals from the CON samples were ranked according to their magnitudes,
and those with values lower than that of the background/baseline (60) were defined as absent and excluded. There were just 92 genes passing these criteria, of which the
top 40 are presented. The fates of the expressions of these genes in microvesicles from CPM- or OXP-treated samples were also assessed. Data were generated from two
biological replicates.
Table 2 Identifying genes specific to OXP
Gene expression
Symbol Notes CON CPM OXP CPM/CON OXP/CON
Falls
RPL7L1 Ribosomal protein 325 327 51 1.00 0.16
GJC1 Gap junction protein 282 295 50 1.04 0.18
FKTN Fukutin 255 277 47 1.09 0.19
PNPT1 Polynucleotide phosphorylase 1 336 309 66 0.92 0.20
IL18 Supports NK action and stimulates the production of IFNg by T-cells 330 304 76 0.92 0.23
LILRB1 Leukocyte immunoglobulin-like receptor 1 230 253 59 1.1 0.26
GABPB2 GA-binding protein transcription factor b subunit 2 395 371 194 0.94 0.49
Rises
MAP4K4 MAPK member that has a role in the response to stress and cytokines 50 52 100 1.0 2.0
RHBDF2 Rhomboid-like protein 48 48 143 1.0 3.0
KRIT1 Ankyrin repeat-containing proteins involved with cytoskeletal processes 63 68 196 1.1 3.1
BCL7C May be involved in anti-apoptotic responses 54 49 180 0.90 3.3
ABCA4 ATP-binding cassette 54 52 204 0.98 3.8
MAP1A Microtubule protein involved with cytoskeletal re-arrangements 72 69 371 0.96 5.1
Abbreviations: BCL7C¼ B-Cell lymphoma 7C; CON¼ control; CPM¼Cyclophosphamide; OXP¼ oxaliplatin. Genes were filtered according to the criteria that expressions be
(i) o10% different between untreated and CPM-treated, and (ii)41-fold change in either direction between untreated and OXP-treated. This was done to generate a list of
genes whose expressions were altered by treatment with OXP, but not by CPM. The ratios of expressions in CPM/control (CON) and OXP/CON are also shown. Data were
generated from two biological replicates.
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automatically factored in. Our initial intention was to use this
methodology as a way of first, establishing if any the presence of
RNA transcripts; and second, to identify those that were found. We
intentionally did not treat these microvesicles with RNAse to
remove surface RNA, as physiologically, these may also have a
putative role in communication. Additionally, it was not our focus
to discriminate the individual components of the microvesicles
(Simpson et al, 2008), and thus treated them as one entity. Results
of the gene expression analysis revealed just 92 genes out of a
possible 28 557 genes (0.32%) were found in the microvesicles. A
number of these genes were primarily associated with transcrip-
tion and immune function, which reinforced our initial studies
that suggested tumour-derived supernatants were exploitable
targets for chemotherapy with regards to enhancing immunosur-
veillance and immune function (Liu et al, 2010, 2012). Interest-
ingly, the results of this analysis also identified a cohort of genes
specifically involved in angiogenesis was also represented in the
microvesicles.
To address the suggestion that supernatants were able to
influence angiogenesis, we next assessed the ability of tumour
supernatants to re-organise HUVECs into primitive tube-struc-
tures on Matrigel. We first demonstrated an increased active state
of intracellular molecules ERK and AKT in HUVECs, which are
important protagonists intimately associated with the angiogenesis
(Carmeliet and Jain, 2011), following treatment with supernatants
from tumours. The phenotypic consequence of this was significant
increases in tube formation by HUVECs. This is not only seen
in complete supernatants, but also seen when HUVECs were
stimulated specifically with the cytokine fraction of deconstructed
supernatant. This was a possible reflection of the pro-angiogenic
factors detected by the immunoassays. Moreover, a primitive
network of tubes was also seen after treatment with microvesicles,
albeit to a much lower extent. This effect has been reported
recently in chronic myeloid leukaemia (Taverna et al, 2011). Our
data also suggested that treating tumour cells with OXP may have
resulted in microvesicles that were more angiogenic in nature, as
there was a modest increase in tubulogenesis following culture
with these microvesicles. Although this increase was not statisti-
cally significant (1124±84 vs 842±91 using untreated tumour
microvesicles; P¼ 0.064), we are currently exploring the fascinat-
ing notion that chemotherapy may modify the microvesicular
output of tumours, which may influence the tumour–host
relationship. Equally, we are also investigating the fundamental
nature of the microvesicular fraction, which may be sufficiently
altered by different chemotherapies to cause differences in
macroscopic effects. For instance, OXP may cause there to be
being more apoptosomes within the microvesicular portion of
supernatants.
Thus, it appears that tumours are capable of depositing into
the microenvironment factors that benefit growth, which may
represent a mode by which tumours promote metastasis. For this
reason, antagonising the action of these factors would be
therapeutically attractive. Indeed, we have previously shown that
negating the effects of cytokines exuded by peripheral blood
mononuclear cells can drastically potentiate cytolytic T-cell
activity (Liu et al, 2011). Therefore, we assessed the impact that
culturing tumour cells with CPM and OXP would have on the
composition of supernatants. Our earlier studies had already
defined a benefit to immune function of these supernatants
(Liu et al, 2010, 2012), and although the current study was tasked
to explore this further, we instead focused on the effects that
chemotherapy may have on the angiogenesis-promoting character
of tumour supernatants, as well dissecting the roles that the indivi-
dual parts of the supernatant may possess. Our results showed that
treating tumour cells with OXP, altered the profile of the super-
natant exuded by the tumours to render them less angiogenic in
nature. Parenthetically, treating tumour cells with an equi-active
concentration of CPM did not affect the angiogenic quality of the
supernatant, which was manifest as a lack of an impact on tubulo-
genic action in HUVECs. This highlights the intrinsic differences
in the mechanisms of action for these two drugs that produced
such divergent effects; indeed, we have shown previously
supernatants from A549 cells have distinct immune stimulatory
activity (Liu et al, 2012), which can only be a reflection of the
way that these agents work and the intracellular pathways that are
affected.
In summary, the current study initially tasked to explicate
results of our earlier studies showing an immunity-enhancing
effect of common chemotherapy has instead highlighted an effect
of the chemotherapy on angiogenesis. The effect of chemotherapy
was indirect, and caused by modifications to supernatants
produced by tumours following treatment with the drugs. The
idea that supernatants produced by tumours that are fundamen-
tally supportive of tumour growth can be disrupted by chemother-
apy, as well as their being capable of enhancing immune responses,
suggests substances are capable of being transmitted from cell to
cell. This form of communication that in part regulates tumour
development thus forms a new therapeutic target, which presents
an interesting avenue for research. For instance, using blocking
antibodies to negate the actions of the cytokines within the
supernatants may prove fruitful, and suggests a benefit of
combining agents with overlapping functions to counter the
impact of tumour exudates. This is another particular area of
research that we are pursuing.
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